1. Home
  2. TKNO vs GLUE Comparison

TKNO vs GLUE Comparison

Compare TKNO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TKNO
  • GLUE
  • Stock Information
  • Founded
  • TKNO 1996
  • GLUE 2019
  • Country
  • TKNO United States
  • GLUE United States
  • Employees
  • TKNO N/A
  • GLUE N/A
  • Industry
  • TKNO Medicinal Chemicals and Botanical Products
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • TKNO Health Care
  • GLUE Health Care
  • Exchange
  • TKNO Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • TKNO 256.9M
  • GLUE 351.2M
  • IPO Year
  • TKNO 2021
  • GLUE 2021
  • Fundamental
  • Price
  • TKNO $4.35
  • GLUE $4.80
  • Analyst Decision
  • TKNO
  • GLUE Buy
  • Analyst Count
  • TKNO 0
  • GLUE 2
  • Target Price
  • TKNO N/A
  • GLUE $13.50
  • AVG Volume (30 Days)
  • TKNO 224.0K
  • GLUE 369.2K
  • Earning Date
  • TKNO 08-07-2025
  • GLUE 08-07-2025
  • Dividend Yield
  • TKNO N/A
  • GLUE N/A
  • EPS Growth
  • TKNO N/A
  • GLUE N/A
  • EPS
  • TKNO N/A
  • GLUE 0.29
  • Revenue
  • TKNO $38,923,000.00
  • GLUE $177,986,000.00
  • Revenue This Year
  • TKNO $9.52
  • GLUE $83.76
  • Revenue Next Year
  • TKNO $15.20
  • GLUE N/A
  • P/E Ratio
  • TKNO N/A
  • GLUE $16.32
  • Revenue Growth
  • TKNO 11.40
  • GLUE 2990.57
  • 52 Week Low
  • TKNO $4.00
  • GLUE $3.50
  • 52 Week High
  • TKNO $10.37
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • TKNO 43.35
  • GLUE 51.69
  • Support Level
  • TKNO $4.22
  • GLUE $4.54
  • Resistance Level
  • TKNO $4.94
  • GLUE $4.93
  • Average True Range (ATR)
  • TKNO 0.29
  • GLUE 0.21
  • MACD
  • TKNO -0.00
  • GLUE 0.06
  • Stochastic Oscillator
  • TKNO 16.75
  • GLUE 81.43

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: